Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

about

Drugs for benign prostatic hypertrophy Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis

P2860

Q58588902-56428223-370C-4F3D-89E9-B539FD847937 Q58699810-9F1EB9A2-ADD1-48E5-9528-0AB7C677BD18

P2860

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Item

http://www.wikidata.org/entity/Q47434739

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@en

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@nl

type

Item

label

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@en

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@nl

prefLabel

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@en

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@nl

P1476

Silodosin for the treatment of ...... benign prostatic hyperplasia.

@en

P2093

Balaji Reddy

http://www.w3.org/2001/XMLSchema#string

Jae Hung Jung

http://www.w3.org/2001/XMLSchema#string

Jiye Kim

http://www.w3.org/2001/XMLSchema#string

Myung Ha Kim

http://www.w3.org/2001/XMLSchema#string

Philipp Dahm

http://www.w3.org/2001/XMLSchema#string

Roderick MacDonald

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration

What is "quality of evidence" and why is it important to clinicians?

Measuring inconsistency in meta-analyses

Quantifying heterogeneity in a meta-analysis

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.

Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.

Benign prostatic hyperplasia: from bench to clinic

P304

CD012615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/14651858.CD012615.PUB2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29161773

http://www.w3.org/2001/XMLSchema#string

P932

6486059

http://www.w3.org/2001/XMLSchema#string

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

about

P2860

P2860

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932